亚洲精品成人一区-亚洲精品成人网久久久久久-亚洲精品成人久久久影院-亚洲精品成人久久-黑人巨大白妞出浆-黑人巨大vs小早川怜子

HJC黄金城

Innovate

科學(xué)創(chuàng)新

科學(xué)創(chuàng)新

HJC黄金城擁有完整細(xì)胞藥物開(kāi)發(fā)平臺(tái)，滿(mǎn)足多種臨床需求

STAR-T平臺(tái)

具有自主知識(shí)產(chǎn)權(quán)的合成性T細(xì)胞受體抗原受體( Synthetic TCR and Antigen Receptor), STAR-T細(xì)胞治療技術(shù)平臺(tái)。
與當(dāng)前細(xì)胞治療領(lǐng)域常用的CAR-T技術(shù)相比，STAR-T更具有天然T細(xì)胞的特性，具有天然雙靶點(diǎn)，毒性低，耗竭慢，浸潤(rùn)性強(qiáng)的特點(diǎn)，更有可能實(shí)現(xiàn)對(duì)實(shí)體瘤治療的突破。

定點(diǎn)整合技術(shù)

自研的定點(diǎn)整合技術(shù)是一種基因編輯 T細(xì)胞的顛覆性突破技術(shù)，可通過(guò)非電轉(zhuǎn)體系在指定位點(diǎn)插入目的基因，該技術(shù)對(duì)T細(xì)胞損傷小、易于工業(yè)化放大、成本低。
其結(jié)合STAR平臺(tái)的定點(diǎn)整合可代償內(nèi)源TCR被敲除的缺陷，開(kāi)發(fā)革命性的通用型T細(xì)胞產(chǎn)品。




相關(guān)新聞和發(fā)表文章

[1]A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL). Blood. November 5, 2020.

[2]Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL. Hematology News. December 14, 2020.

[3]Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors.Sci Transl Med. Mar 24,2021.

[4]A Novel CMV-Specific TCR-T Cell Therapy Is Effective and Safe for Refractory CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation. ASH Meeting. December 13, 2021.

[5]A novel CD19/CD20 dual synthetic T-cell receptor and antigen receptor (STAR) T cell therapy for refractory and relapsed (R/R) B cell acute lymphoblastic leukemia (B-ALL). EHA Library.. 06/09/2021; 324526; S118.

[6] A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia. American Journal of Hematology.01 May 2022